A novel self-assembled nanoparticle vaccine with HIV-1 Tat 49-57/HPV16 E7 49-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8 + T cell-dependent anti-tumor immunity in mice

Vaccine

Volumn 30, Issue 6, 2012, Pages 1071-1082

  Tang, Jun ^a,b   Yin, Rui ^a   Tian, Yi ^a   Huang, Zeming ^a   Shi, Jinglei ^a   Fu, Xiaolan ^a   Wang, Li ^a   Wu, Yuzhang ^a   Hao, Fei ^a   Ni, Bing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b The 105th Hospital of PLA   (China)

Author keywords

E7 49 57; GM CSF; HIV Tat 49 57; HPV; Nanoparticle

Indexed keywords

CANCER VACCINE; DEOXYRIBONUCLEASE I; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLASMID VECTOR; PROTEIN E7; TAT E7 FUSION PEPTIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; EX VIVO STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOASSAY; IN VIVO STUDY; LONG TERM SURVIVAL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV-1; HUMAN PAPILLOMAVIRUS 16; MICE; MICE, INBRED C57BL; NANOPARTICLES; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINES, DNA;

EID: 84856320301     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.029     Document Type: Article

References (38)

1. Stanley M. The epidemiology and burden of HPV disease. Nurs Times 2008, 104(September (36)):38-40.
2. Lin K., Roosinovich E., Ma B., Hung C.F., Wu TC Therapeutic HPV DNA vaccines. Immunol Res 2010, 47(July (1-3)):86-112.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(May (5)):342-350.
4. Roden R.B., Ling M., Wu T.C. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004, 35(August (8)):971-982.
5. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169(July (1)):350-358.
6. *0201 transgenic mice. Cancer Res 2002, 62(October (20)):5792-5799.
7. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88(July (1)):202-210.
8. Chauhan A., Tikoo A., Kapur A.K., Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 2007, 117(February (2)):148-162.
9. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997, 159(August (4)):1666-1668.
10. Leifert J.A., Holler P.D., Harkins S., Kranz D.M., Whitton J.L. The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes. Gene Ther 2003, 10(December (25)):2067-2073.
11. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23(September (9)):2242-2249.
12. Sadovnikova E., Zhu X., Collins S.M., Zhou J., Vousden K., Crawford L., et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 1994, 6(February (2)):289-296.
13. Esposito C., Generosi J., Mossa G., Masotti A., Castellano A.C. The analysis of serum effects on structure, size and toxicity of DDAB-DOPE and DC-Chol-DOPE lipoplexes contributes to explain their different transfection efficiency. Colloids Surf B: Biointerfaces 2006, 53(December (2)):187-192.
14. Wu Y.Z., Zhao J.P., Wan Y., Jia Z.C., Zhou W., Bian J., et al. Mimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivo. J Virol 2002, 76(October (20)):10264-10269.
15. Harbottle R.P., Cooper R.G., Hart S.L., Ladhoff A., McKay T., Knight A.M., et al. An RGD-oligolysine peptide: a prototype construct for integrin-mediated gene delivery. Hum Gene Ther 1998, 9(May (7)):1037-1047.
16. Giannouli C., Brulet J.M., Gesche F., Rappaport J., Burny A., Leo O., et al. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res 2003, 23(July-August (4)):3523-3531.
17. Ko S.Y., Ko H.J., Chang W.S., Park S.H., Kweon M.N., Kang C.Y. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005, 175(September (5)):3309-3317.
18. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60(February (4)):1035-1042.
19. Hsieh C.J., Kim T.W., Hung C.F., Juang J., Moniz M., Boyd D.A., et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004, 22(September (29-30)):3993-4001.
20. Kim D., Hoory T., Monie A., Ting J.P., Hung C.F., Wu T.C. Enhancement of DNA vaccine potency through co-administration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008, 180(May (10)):7019-7027.
21. Feltkamp M.C., Vreugdenhil G.R., Vierboom M.P., Ras E., van der Burg S.H., ter Schegget J., et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995, 25(September (9)):2638-2642.
22. Torrens I., Mendoza O., Batte A., Reyes O., Fernandez L.E., Mesa C., et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 2005, 23(December (50)):5768-5774.
23. Giannouli C., Brulet J.M., Gesché F., Rappaport J., Burny A., Leo O.A., et al. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res 2003, 23(Jul-Aug (4)):3523-3531.
24. Toubaji A., Hill S., Terabe M., Qian J., Floyd T., Simpson R.M., et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007, 25(August (31)):5882-5891.
25. Lin K., Doolan K., Hung C.F., Wu T.C. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010, 109(January (1)):4-24.
26. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat Biotechnol 2000, 18(January (1)):33-37.
27. Awasthi S., Cox R.A. Transfection of murine dendritic cell line (JAWS II) by a nonviral transfection reagent. Biotechniques 2003, 35(September (3)):600-602. 604.
28. Karkada M., Weir G.M., Quinton T., Sammatur L., MacDonald L.D., Grant A., et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother 2010, 33(April (3)):250-261.
29. Perez S.A., Kallinteris N.L., Bisias S., Tzonis P.K., Georgakopoulou K., Varla-Leftherioti M., et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2011, 16(July (13)):3495-3506.
30. Kaufman H.L., Kim D.W., DeRaffele G., Mitcham J., Coffin R.S., Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010, 17(March (3)):718-730.
31. Gritzapis A.D., Voutsas I.F., Lekka E., Papamichail M., Baxevanis C.N. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 2010, 70(April (7)):2686-2696.
32. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007, 18(February (2)):226-232.
33. Berry C.C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine (Lond) 2008, 3(June (3)):357-365.
34. Vives E., Richard J.P., Rispal C., Lebleu B. TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci 2003, 4(April (2)):125-132.
35. Hauser H., Shen L., Gu Q.L., Krueger S., Chen S.Y. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 2004, 11(June (11)):924-932.
36. Dalpke A., Zimmermann S., Heeg K. Immunopharmacology of CpG DNA. Biol Chem 2002, 383(October (10)):1491-1500.
37. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
38. Kline J.N., Krieg A.M. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect 2008, 21(October (8)):434-439.